Physiopathology and Sequelae of COVID-19 Infection

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04563676

Acronym

SEQ-COV-PHYSIO

Enrollment

400

Registered

2020-09-24

Start date

2020-09-22

Completion date

2025-12-31

Last updated

2025-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cortisol, Covid19, TSH

Keywords

Covid19, TSH, cortisol

Brief summary

The data obtained from Covid-19 infections seem to suggest that the immunogenesis of Covid-19 could in some cases be the result of immune dysregulation. On the other hand, endocrine damage is possible at the tile of Covid-19 infection (mainly thyroid,adrenal, and hypothalamus). These disorders are autoimmune or linked to degeneration. The main objective is to assess the thyroid function (thyrotropic axis) as well as the corticotropic adrenal function of patients who have had Copvid-19 pneumonia. The secondary objectives is to describe the pathophysiological mechanisms of pulmonary and vasculothrombotic involvement of Covid-19

Interventions

BIOLOGICALblood test

covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient having a covid19 infection hospitalized at the Amiens Picardie University Hospital * Patient who is seen in Pneumology consultation for a respiratory assessment at 3 months of his hospitalization (between M2 and M4) to evaluate presence of respiratory sequelae * Patient who agreed to participate in the protocol * Patient affiliated to a Social Security

Exclusion criteria

* patient under guardianship or curators * patient refusing to participate

Design outcomes

Primary

Measure	Time frame	Description
8-hour cortisol level in patients with Covid19 pneumonia	day 0	8-hour cortisol level in patients with Covid19 pneumonia will be determined the day of consultation for respiratory sequelae.
TSH level in patients with Covid19 pneumonia	day 0	TSH level in patients with Covid19 pneumonia will be determined the day of consultation for respiratory sequelae.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026